DETEC Esterase for Screening Wound Infection at Point of Care

  • End date
    Dec 25, 2022
  • participants needed
  • sponsor
    Progenitec Inc.
Updated on 26 January 2021


This non-interventional, single-blinded, prospective, observational study assesses the planar distribution of leukocyte esterase in wounds by measuring wound exudates-soaked wound dressings using the DETEC Esterase device during routine wound care. The output of the device is correlated with the clinical determination of infection to assess the device efficacy in identifying presumptive infections.


Qualitative measures of leukocyte esterase have been used clinically as a biomarker to screen for various infectious diseases including urinary tract infections, peritonitis and joint infections. It is likely that wound infection is also accompanied with the elevation of leukocyte esterase in wound fluid and on the wound dressing. To test this hypothesis, the proposed device - DETEC Esterase - has been developed to detect elevated leukocyte esterase on wound exudates absorbed on the wound contacting surface of wound dressings. With increasing esterase levels, this coloration (from colorless/pink to dark purple) becomes more intense indicating infection.

Patients presenting themselves to the clinic with ulcer wounds will be assessed by the clinicians. Those with or without clinical signs and symptoms of a wound infection will be enrolled and recorded in the study. The participant's first visit can be concurrent with enrollment. During this visit, the leukocyte esterase on wounds will be assessed by testing wound exudate adsorbed on to participants' wound dressings using the DETEC Esterase device by a project nurse/tester not involved with subjects' wound management and the output recorded. Wounds will be managed by the clinicians who are blinded from the device output. Consequently, the clinician will send the wound fluids/tissue samples from patients for microbiological laboratory testing. Within 15 days following the first visit, the presence or absence of infection will then be adjudicated by the provider based on all information. The device output will then be correlated with this adjudication.

Condition Varicose Ulcer, Venous stasis, Decubitus Ulcer, Diabetic Foot, Bed Sores (Decubitus Ulcers), Diabetic Foot Ulcers, Pressure Ulcers, Pressure Ulcer, diabetic foot ulcer, venous ulcers, venous ulcer, pressure sores, decubitus, bedsore
Treatment DETEC® Esterase
Clinical Study IdentifierNCT04614870
SponsorProgenitec Inc.
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 21 yrs?
Gender: Male or Female
Do you have any of these conditions: Pressure Ulcers or Pressure Ulcer or diabetic foot ulcer or Bed Sores (Decubitus Ulcers) or venous ulcers or decubitus or bedsore or Decubitus Ulcer o...?
Do you have any of these conditions: pressure sores or Bed Sores (Decubitus Ulcers) or diabetic foot ulcer or bedsore or Venous stasis or decubitus or Pressure Ulcers or venous ulcer or D...?
Adult (21 years), male or female, inpatient/outpatient, presenting with a wound
Chronic wound of multiple etiologies for at least 30 days, including (Diabetic foot ulcers, Wagner grade 1 to 3), (Pressure ulcers, stage 2 to 4), (Venous leg ulcers, confirmed by venous duplex)
For leg or foot ulcers (e.g. DFU, VLU) an ankle-brachial index (ABI) measured on the limb with the ulcer of greater than 0.6
For diabetic foot ulcers - confirmed type 1 or type 2 diabetes mellitus with a hemoglobin A1C less than 12 percentage (or less than 107.65 millimoles per mole)

Exclusion Criteria

History of autoimmune disease/ acquired immunodeficiency syndrome/Hepatitis
Require treatment for primary or metastatic malignancy
Any contra-indication to routine wound care and/or monitoring
Women who are pregnant, lactating, or of childbearing potential and not currently taking adequate birth control
Scheduled for or likely to have significant surgical intervention to the studied wound (e.g. skin graft or flap, amputation) during the study period
With a life expectancy of less than 6 months
Participation (less than 30 days prior to baseline) in an interventional trial which could have a potential effect on the study outcome, as determined by the Investigator
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note